Follow the 화일약품 stock price and the full directors' dealings record of the company, a listed issuer based in South Korea. Shares are quoted on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, 화일약품 has recorded 65 public disclosures. Market capitalisation: €74.9bn. The latest transaction was reported on 2 July 2026 (Purchase). Among the most active insiders: CG인바이츠. Every trade is free.
64
Insider Decl.
n/a
Thresholds
€2,733
25 ops.
Buy Volume
€1m
17 ops.
Sell Volume
24Σ signal
Buys €2,733€1m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 17,526 of 29,064 companies
45.8
score / 100
Value
54
Quality
38
FCF yld8.2%
Earn yld-0.2%
EV/EBITDA·
ROE1.9%
Gross mgn6.6%
Net mgn-0.2%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
화일약품 es una empresa de salud y farmacéutica que cotiza en el mercado XKRX. Se especializa en la fabricación de productos farmacéuticos y soluciones para el cuidado de la salud.